Lakefront Biotherapeutics (LKFT)

$27.45 -1.14 (-3.99%)
Market Cap N/A
Revenue (ttm) 1.11B
Net Income (ttm) 320.88M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 28.85%
Debt to Equity Ratio 0.00
Volume 194,400
Avg Vol 166,954
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 12%
Beta N/A
Analysts Hold
Price Target $30.17
Latest News on LKFT
Galapagos Reports First Quarter 2026 Financial Results and Provides Business Update

Wed, 06 May 2026 16:01:00 -0400 - 6 days ago

Galapagos Reports First Quarter 2026 Financial Results and Provides Business Update

Galapagos' Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders' Meetings 2026

Tue, 28 Apr 2026 16:01:00 -0400 - 14 days ago

Galapagos' Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders' Meetings 2026

Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases

Tue, 31 Mar 2026 01:30:00 -0400 - 6 weeks ago

Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases

Galapagos Announces Nomination of Gino Santini to its Board of Directors

Thu, 26 Mar 2026 16:02:00 -0400 - 6 weeks ago

Galapagos Announces Nomination of Gino Santini to its Board of Directors

Galapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders' Meetings

Thu, 26 Mar 2026 16:01:00 -0400 - 6 weeks ago

Galapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders' Meetings

Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases

Mon, 23 Mar 2026 18:25:00 -0400 - 7 weeks ago

Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases

Galapagos Receives Transparency Notification from Bank of America

Tue, 17 Mar 2026 17:01:00 -0400 - 2 months ago

Galapagos Receives Transparency Notification from Bank of America

Galapagos Receives Transparency Notifications from Bank of America

Tue, 10 Mar 2026 17:01:00 -0400 - 2 months ago

Galapagos Receives Transparency Notifications from Bank of America

Galapagos Creates New Subscription Right Plan

Fri, 06 Mar 2026 16:01:00 -0500 - 2 months ago

Galapagos Creates New Subscription Right Plan

Galapagos Appoints Tania Philipp as Chief Human Resources Officer

Thu, 05 Mar 2026 16:01:00 -0500 - 2 months ago

Galapagos Appoints Tania Philipp as Chief Human Resources Officer

Galapagos Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

Mon, 23 Feb 2026 16:01:00 -0500 - 2 months ago

Galapagos Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities

Mon, 05 Jan 2026 16:01:00 -0500 - 4 months ago

Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities

Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025

Mon, 08 Dec 2025 01:30:00 -0500 - 5 months ago

Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025

Galapagos to Present New Data from Cell Therapy Program at ASH 2025

Mon, 03 Nov 2025 16:01:00 -0500 - 6 months ago

Galapagos to Present New Data from Cell Therapy Program at ASH 2025

Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors

Thu, 23 Oct 2025 16:01:00 -0400 - 7 months ago

Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors

Biotech firm Galapagos to wind down cell therapy business

Tue, 21 Oct 2025 03:34:50 -0400 - 7 months ago

Biotech firm Galapagos to wind down cell therapy business

Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company's Ongoing Transformation

Tue, 21 Oct 2025 01:30:00 -0400 - 7 months ago

Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company's Ongoing Transformation

Galapagos Announces Appointment of Fred Blakeslee as General Counsel

Thu, 16 Oct 2025 16:01:00 -0400 - 7 months ago

Galapagos Announces Appointment of Fred Blakeslee as General Counsel

Biotechnology firm Galapagos receives offers for cell-therapy business

Wed, 01 Oct 2025 16:12:26 -0400 - 7 months ago

Biotechnology firm Galapagos receives offers for cell-therapy business

Galapagos Provides Update on Strategic Alternatives for Its Cell Therapy Business

Wed, 01 Oct 2025 16:01:00 -0400 - 7 months ago

Galapagos Provides Update on Strategic Alternatives for Its Cell Therapy Business

Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Wed, 06 Aug 2025 01:30:00 -0400 - 9 months ago

Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation

Wed, 23 Jul 2025 16:03:00 -0400 - 10 months ago

Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation

Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of Directors

Wed, 23 Jul 2025 16:02:00 -0400 - 10 months ago

Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of Directors

Galapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter Business Update

Wed, 23 Jul 2025 16:01:00 -0400 - 10 months ago

Galapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter Business Update

Galapagos Appoints Aaron Cox as Chief Financial Officer

Mon, 23 Jun 2025 01:30:00 -0400 - 11 months ago

Galapagos Appoints Aaron Cox as Chief Financial Officer

Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101

Wed, 18 Jun 2025 16:01:00 -0400 - 11 months ago

Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101

Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL

Thu, 12 Jun 2025 16:01:00 -0400 - 11 months ago

Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL

Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes

Tue, 13 May 2025 01:36:00 -0400 - 1 year ago

Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes

Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts

Wed, 23 Apr 2025 16:01:00 -0400 - 1 year ago

Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts

Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025

Tue, 15 Apr 2025 01:30:00 -0400 - 1 year ago

Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025

Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders' Meeting

Thu, 27 Mar 2025 16:01:00 -0400 - 1 year ago

Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders' Meeting

Galapagos to Present at Upcoming Investor Conferences

Mon, 24 Feb 2025 16:01:00 -0500 - 1 year ago

Galapagos to Present at Upcoming Investor Conferences

Galapagos receives transparency notification and 13D filing from Tang Capital

Mon, 17 Feb 2025 16:01:00 -0500 - 1 year ago

Galapagos receives transparency notification and 13D filing from Tang Capital

Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update

Wed, 12 Feb 2025 16:01:00 -0500 - 1 year ago

Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update

Galapagos To Spin Off Innovative Medicines Business

Tue, 21 Jan 2025 12:08:16 -0500 - 1 year ago

Galapagos To Spin Off Innovative Medicines Business

Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities

Wed, 08 Jan 2025 01:30:00 -0500 - 1 year ago

Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities

Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Tue, 07 Jan 2025 16:01:00 -0500 - 1 year ago

Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Sat, 07 Dec 2024 12:30:00 -0500 - 1 year ago

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024

Tue, 05 Nov 2024 16:01:00 -0500 - 1 year ago

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024

Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update

Wed, 30 Oct 2024 16:01:00 -0400 - 1 year ago

Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update

Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

Mon, 07 Oct 2024 01:00:00 -0400 - 1 year ago

Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

Excellos Selected as Decentralized Manufacturing Unit to Support Galapagos' CAR-T Cell Therapy Clinical Study Close to Cancer Treatment Centers in the San Diego Area

Tue, 01 Oct 2024 06:00:00 -0400 - 1 year ago

Excellos Selected as Decentralized Manufacturing Unit to Support Galapagos' CAR-T Cell Therapy Clinical Study Close to Cancer Treatment Centers in the San Diego Area

Galapagos receives transparency notification from EcoR1 Capital

Mon, 30 Sep 2024 16:01:00 -0400 - 1 year ago

Galapagos receives transparency notification from EcoR1 Capital

Galapagos receives transparency notification from FMR LLC

Tue, 03 Sep 2024 16:01:00 -0400 - 1 year ago

Galapagos receives transparency notification from FMR LLC

Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma

Fri, 23 Aug 2024 01:00:00 -0400 - 1 year ago

Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma

BridGene Biosciences Expands Strategic Collaboration with Galapagos to Develop Selective Oral SMARCA2 PROTAC in Precision Oncology

Thu, 01 Aug 2024 16:01:00 -0400 - 1 year ago

BridGene Biosciences Expands Strategic Collaboration with Galapagos to Develop Selective Oral SMARCA2 PROTAC in Precision Oncology

Galapagos reports half-year 2024 financial results and provides second quarter business update

Thu, 01 Aug 2024 16:01:00 -0400 - 1 year ago

Galapagos reports half-year 2024 financial results and provides second quarter business update

Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024

Fri, 14 Jun 2024 16:01:00 -0400 - 2 years ago

Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024

Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications

Thu, 30 May 2024 16:01:00 -0400 - 2 years ago

Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

Thu, 30 May 2024 16:01:00 -0400 - 2 years ago

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications